dnk333
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2003 (NCT01287325)
Timeline
Indications
Mechanism of action
- Neurokinin 1 receptorANTAGONIST
TACR1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CN(C(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)[C@@H](/C=C/C(=O)N[C@@H]1CCCCNC1=O)Cc1ccc(Cl)c(Cl)c1- Mol. weight
- 624.41 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL105060 ↗
Also known as
- dnk333
- dnk333
- dnk333
- dnk333
- dnk 333
- dnk 333
- dnk-333
- dnk-333
- dnk-333
- n-((r,r)-(e)-1-(3,4-dichlorobenzyl)-3-(2-oxoazepan-3-yl)carbamoyl)allyl-n-methyl-3,5-bis(trifluoromethyl)benzamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01033097 | Phase 2 | Nov 1, 2009 | Novartis |
| NCT00394173 | Phase 2 | Sep 1, 2006 | Novartis |
| NCT00699166 | Phase 2 | Apr 1, 2004 | Novartis |
| NCT01287325 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2003 | Novartis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 4 | 4 | 1 | 2003 |
1 organizations
Page 1 / 1